sacituzumab govitecan
gilead sciences
['trodelvy', 'breast', 'fierce']
#asco22 with a 1.5-month median pfs improvement, gilead's trodelvy data in hr+/her2- breast cancer don't meet doctors' expectations. 
Tweets from the Fierce Life Sciences editorial team